

CHRONIC BREATHLESSNESS

From a light bulb moment in clinical practice to a world first registration

1998

Ethics application submitted for crossover study

2003

First adequately powered crossover study published

2008

Australian community data on defining the burden of chronic breathlessness

2011

Dose ranging and long term effectiveness study published

2014

Phase 3 clinical trial closes

2018

Submission



2019

Approval

2019

Subsidy

TGA

Therapeutic Goods Administration

MEDICINE

AVAILABLE

PBS

Pharmaceutical Benefits Scheme

MEDICINE

AFFORDABLE


250,000

Living with chronic breathlessness



5 YEAR STUDY

14



AUSTRALIAN HOSPITALS

284

PATIENTS

**PHASE 3
CLINICAL TRIAL**



maynepharma

**INDUSTRY
PARTNERSHIP**



**WORLD FIRST
REGISTRATION**

**CLINICAL
OBSERVATION**

People with breathlessness seem to improve with

MORPHINE

